Oncology Clinical Pathways Spotlight
This week in health care trends, our oncology clinical pathways spotlight includes: the factors surrounding the proliferation of pathways, the flaws in a bundled payments approach to high cancer costs, and the future of clinical pathways.
This article delves into the factors behind the proliferation of clinical pathways in oncology, including the “tipping point” that’s causing more and more stakeholders to incorporate value into their decision-making processes.
JOP Editorial Examines Bundled Payment Approaches in Oncology, Proposes Inclusion of Value-Based Pathways to Enhance System
This ASCO Post article summarizes a JOP report that argues that there are some fundamental flaws in a bundled-payment approach to cost, because “while drug costs are rapidly growing, cancer drugs are not responsible for the largest variability in cancer care spending, and drug-related spending is not as easy to control as the bundled payment system presumes.”
At a recent AJMC panel discussion, experts debated “where they see the need for improvement in clinical pathways and what they think the future holds for this field,” including the relationship between pathways and utilization and the need to compare different pathways.
The articles above are from our dedicated Oncology Clinical Pathways e-magazine. Follow us on Flipboard or Twitter, or just watch for the links to this and our other magazines in our regular weekly BioBlog emails. (Don’t get our emails yet? Subscribe here!)